Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.

Slides:

Advertisements

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Advertisements

The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection.

Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.

Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma Hideyuki Imoto, MD, Toshihiro.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Primary Mucoepidermoid Carcinoma of the Esophagus

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

A Novel Classification of MUC1 Expression Is Correlated with Tumor Differentiation and Postoperative Prognosis in Non–Small Cell Lung Cancer Shinjiro.

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

P2-090: Expression of cellular retinol binding protein-1 is associated with poor prognosis of stage I non-small cell lung cancer Moo Suk Park, Yoon Soo.

Difficulties in Diagnosis and Management of Ectopic Cushing Syndrome

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status Young Joo Lee, MD, Heung Tae Kim, MD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non–Small Cell Lung Cancer Junghoon Shin, MD, Bhumsuk Keam, MD, PhD, Miso.

The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao,

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Postoperative Prognosis in Patients with Non-small Cell Lung Cancer According to the Method of Initial Detection Takeshi Hanagiri, MD, PhD, Kenji Sugio,

ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated.

Positron Emission Tomography-Computed Tomography for Postoperative Surveillance in Non-Small Cell Lung Cancer Se Hoon Choi, MD, Young Tae Kim, MD, PhD,

Primary Mucoepidermoid Carcinoma of the Esophagus

Aberrant Wnt1/β-Catenin Expression is an Independent Poor Prognostic Marker of Non- small Cell Lung Cancer After Surgery Xianhua Xu, MD, Ping-Li Sun,

Prognostic Factors in Patients with Pathologic T1-2N1M0 Disease in Non-small Cell Carcinoma of the Lung Katsunari Matsuoka, MD, Shinichi Sumitomo, MD,

Epidermal Growth Factor Receptor Mutation and p53 Overexpression during the Multistage Progression of Small Adenocarcinoma of the Lung Seol Bong Yoo,

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer Jeong-Ok Lee, MD, Tae Min.

Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non–Small-Cell Lung Cancer with Activating EGFR Mutation Bhumsuk.

Clinical Outcomes and Prognosis of Recurrent Thymoma Management

Upregulation of Hypoxia-Inducible Factor-1α mRNA and its Clinical Significance in Non- small Cell Lung Cancer Tomofumi Yohena, MD, Ichiro Yoshino, MD,

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Frequency of Lymph Node Metastasis According to the Size of Tumors in Resected Pulmonary Adenocarcinoma with a Size of 30 mm or Smaller Yangki Seok,

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Valerie W Rusch, MD, Ennapadam S Venkatraman, PhD

Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant.

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for.

Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis Alessandro Marra, MD, PhD, Ludger Hillejan, MD,

Visceral Pleural Invasion Classification in Non-small Cell Lung Cancer

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

Number of Metastatic Lymph Nodes in Resected Non–Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD,

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

It’s All in the “Swerve of the Curve”

Impact of Chronic Obstructive Pulmonary Disease on the Mortality of Patients with Non– Small-Cell Lung Cancer Seung Jun Lee, MD, Jinwoo Lee, MD, Young.

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Significance of Smoking as a Postoperative Prognostic Factor in Patients with Non- small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Kenji Sugio, MD,

International Thymic Malignancies Interest Group: A Way Forward

Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer Eun Young Kim, MD, Young Saing Kim, MD, Inkeun Park, MD,

Validity of International Association for the Study of Lung Cancer Proposals for the Revision of N Descriptors in Lung Cancer Jin Gu Lee, MD, Chang Young.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung Young Tae Kim, MD, PhD, Sun Jung Park, MS,

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Sleeve Lobectomy as an Alternative Procedure to Pneumonectomy for Non-small Cell Lung Cancer Joon Suk Park, MD, Hee Chul Yang, MD, Hong Kwan Kim, MD,

A Review of First-Line Treatment for Small-cell Lung Cancer

Elevated Preoperative C-reactive Protein Predicts Poor Cancer Specific Survival in Patients Undergoing Resection for Non-small Cell Lung Cancer Caroline.

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Presentation transcript:

Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between Primary Non-small Cell Lung Cancer and Metastatic Lymph Nodes and the Significance in Mid- Term Survival Chang Hyun Kang, MD, Bo Gun Jang, MD, Dong-Wan Kim, MD, Doo Hyun Chung, MD, Young Tae Kim, MD, Sanghoon Jheon, MD, Sook-Whan Sung, MD, Joo Hyun Kim, MD Journal of Thoracic Oncology Volume 4, Issue 11, Pages 1307-1312 (November 2009) DOI: 10.1097/JTO.0b013e3181b9f236 Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Immunohistochemical staining of (A) excision repair crosscomplementation group 1 (ERCC1), (B) x-ray repair crosscomplementation group 1 (XRCC1), and (C) βIII-tubulin. Journal of Thoracic Oncology 2009 4, 1307-1312DOI: (10.1097/JTO.0b013e3181b9f236) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 A, Changes in excision repair crosscomplementation group 1 (ERCC1) expression in primary tumors and metastatic lymph nodes. B, Fifty-five percent of patients showed upregulation of metastatic lymph nodes, but downregulation was found in only 8% of patients. Journal of Thoracic Oncology 2009 4, 1307-1312DOI: (10.1097/JTO.0b013e3181b9f236) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 A, Changes in x-ray repair crosscomplementation group 1 (XRCC1) expression in primary tumors and metastatic lymph nodes. B, Fifty-six percent of patients showed upregulation of XRCC1 expression, but only 6% of patients showed downregulation. Journal of Thoracic Oncology 2009 4, 1307-1312DOI: (10.1097/JTO.0b013e3181b9f236) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 A, Changes in βIII-tubulin expression in primary tumor and metastatic lymph nodes. B, βIII-Tubulin expression in metastatic lymph nodes was downregulated in 45% of patients compared with 12% upregulation. Journal of Thoracic Oncology 2009 4, 1307-1312DOI: (10.1097/JTO.0b013e3181b9f236) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Overall survival according to the level of excision repair crosscomplementation group 1 (ERCC1) expression. A, Patients with upregulation of ERCC1 expression in N1 lymph nodes compared with the primary tumor site demonstrate significantly poor prognosis in N1 non-small cell lung cancer (p = 0.024). B, It shows survival curves according to ERCC1 up- or downregulation in N2 lymph nodes. However, the change in ERCC1 expression in N2 lymph node did not affect overall survival. Journal of Thoracic Oncology 2009 4, 1307-1312DOI: (10.1097/JTO.0b013e3181b9f236) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions